Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Experimental Obesity Treatment
Pfizer has announced a strategic funding agreement with Blackstone Life Sciences to support the development of berobenatide, an experimental drug candidate being studied for chronic weight management and obesity-related conditions.
Under the agreement announced on November 11, 2026, funds managed by Blackstone will cover up to $1.5 billion in development costs through 2028. The arrangement is designed to support Pfizer's clinical development programme while preserving financial flexibility for investments across its broader pharmaceutical pipeline.
Funding Structure and Development Milestones
In exchange for the funding, Blackstone will be eligible to receive milestone-based payments over multiple years. These payments will depend on regulatory approval in the United States for monthly injectable berobenatide as a standalone treatment for chronic weight management, as well as the achievement of specified commercial sales milestones.
Blackstone will not receive ownership or development rights in the drug candidate. Pfizer will retain full operational control and decision-making authority over the programme.
The transaction also involves funds managed by Blackstone's perpetual private equity strategy, BXPE, investing alongside Blackstone Life Sciences.
Berobenatide: Pfizer's Monthly GLP-1 Candidate
Berobenatide, also known as PF'3944, is an investigational GLP-1 receptor agonist peptide being developed as a potential once-monthly injectable treatment.
The candidate is being studied for chronic weight management and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnoea.
Pfizer plans to advance more than 20 clinical trials for obesity and related conditions during 2026. This programme includes 10 ongoing or planned Phase 3 trials involving berobenatide.
The company is also exploring the drug as a standalone treatment and in combination with other peptide-based therapies, including amylin analogues.
The treatment remains investigational and has not yet received regulatory approval for these uses. Its safety and effectiveness will need to be established through clinical studies and regulatory review.
Strategic Importance of the Partnership
The agreement reflects the growing use of external financing partnerships in pharmaceutical research and development.
Late-stage clinical programmes can require substantial investment over several years. Collaborations with specialist life sciences investors can help pharmaceutical companies distribute development costs while maintaining resources for other research priorities.
For Pfizer, the partnership supports its efforts to strengthen its cardiometabolic pipeline and expand its presence in the obesity treatment market.
Competition in the Obesity Treatment Market
The obesity drug market has become an important area of competition among pharmaceutical companies, particularly with the growth of GLP-1-based therapies.
Companies are exploring treatments that could offer different dosing schedules, improved convenience and potential benefits for obesity-related health conditions.
Berobenatide's proposed monthly dosing schedule is a key aspect of its development strategy. However, its eventual market potential will depend on clinical results, regulatory decisions, safety data and commercial performance.
The Pfizer-Blackstone agreement highlights the scale of investment required to advance next-generation obesity treatments and the growing role of financial partnerships in pharmaceutical innovation.



